Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?
Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.
Zacks·13h ago
More News
Key Events This Week: Payrolls, CPI And Retail Sales
Key Events This Week: Payrolls, CPI And Retail Sales The next five days will feature an unusual pairing of major US data releases: the January employment report on Wednesday and the January CPI...
Zero Hedge·15h ago
J&J Posts Innovative Medicine Growth in 2025 Amid Stelara Patent Loss
JNJ's Innovative Medicine unit grew sales 4.1% in 2025 despite Stelara'sZER LOE, topping $60B as Darzalex and new drugs offset pressure
Zacks·15h ago
Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?
PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength against looming headwinds.
Smartleaf Asset Management LLC raised its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 60.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 24,748...
MarketBeat·17h ago
White House shares key plan to lower drug costs
You don't need a chart to know prescription drugs are expensive.When a pharmacist rings up a refill that suddenly jumps from a familiar copay to a painful list price, that sticker shock makes...